These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

820 related articles for article (PubMed ID: 30243806)

  • 21. Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction.
    Russell S
    Int J Clin Pharm; 2013 Apr; 35(2):159-72. PubMed ID: 23263796
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials.
    Mannucci E; Monami M
    Adv Ther; 2017 Jan; 34(1):1-40. PubMed ID: 27844335
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide.
    Gerstein HC; Colhoun HM; Dagenais GR; Diaz R; Lakshmanan M; Pais P; Probstfield J; Riddle MC; Rydén L; Xavier D; Atisso CM; Avezum A; Basile J; Chung N; Conget I; Cushman WC; Franek E; Hancu N; Hanefeld M; Holt S; Jansky P; Keltai M; Lanas F; Leiter LA; Lopez-Jaramillo P; Cardona-Munoz EG; Pirags V; Pogosova N; Raubenheimer PJ; Shaw J; Sheu WH; Temelkova-Kurktschiev T;
    Diabetes Obes Metab; 2018 Jan; 20(1):42-49. PubMed ID: 28573765
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of incretin based therapies: clinical trial data.
    White J
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S30-40. PubMed ID: 19801363
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials.
    Karagiannis T; Malandris K; Avgerinos I; Stamati A; Kakotrichi P; Liakos A; Vasilakou D; Kakaletsis N; Tsapas A; Bekiari E
    Diabetologia; 2024 Jul; 67(7):1206-1222. PubMed ID: 38613667
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes.
    Fulcher G; Matthews DR; Perkovic V; de Zeeuw D; Mahaffey KW; Mathieu C; Woo V; Wysham C; Capuano G; Desai M; Shaw W; Vercruysse F; Meininger G; Neal B;
    Diabetes Obes Metab; 2016 Jan; 18(1):82-91. PubMed ID: 26450639
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk of fracture with dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in real-world use: systematic review and meta-analysis of observational studies.
    Hidayat K; Du X; Shi BM
    Osteoporos Int; 2019 Oct; 30(10):1923-1940. PubMed ID: 31134305
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiovascular effectiveness of glucagon-like peptide 1 receptor agonists versus dipeptidyl peptidase-4 inhibitors in type 2 diabetes: A meta-analysis based on propensity score-matched studies.
    Xu L; Zheng XQ; Liao XX
    Prim Care Diabetes; 2022 Feb; 16(1):207-210. PubMed ID: 34953749
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis.
    Andreadis P; Karagiannis T; Malandris K; Avgerinos I; Liakos A; Manolopoulos A; Bekiari E; Matthews DR; Tsapas A
    Diabetes Obes Metab; 2018 Sep; 20(9):2255-2263. PubMed ID: 29756388
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study.
    Yang CT; Yang CY; Ou HT; Kuo S
    Cardiovasc Diabetol; 2020 Jun; 19(1):83. PubMed ID: 32534570
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Once-weekly dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a systematic review and meta-analysis.
    Stoimenis D; Karagiannis T; Katsoula A; Athanasiadou E; Kazakos K; Bekiari E; Matthews DR; Tsapas A
    Expert Opin Pharmacother; 2017 Jun; 18(9):843-851. PubMed ID: 28448177
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes mellitus.
    Davies M; Speight J
    Diabetes Obes Metab; 2012 Oct; 14(10):882-92. PubMed ID: 22420869
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus--a retrospective nationwide study.
    Mogensen UM; Andersson C; Fosbøl EL; Schramm TK; Vaag A; Scheller NM; Torp-Pedersen C; Gislason G; Køber L
    Diabetes Obes Metab; 2014 Oct; 16(10):1001-8. PubMed ID: 24827939
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparing SGLT-2 inhibitors to DPP-4 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes: A systematic review and meta-analysis.
    Mishriky BM; Tanenberg RJ; Sewell KA; Cummings DM
    Diabetes Metab; 2018 Mar; 44(2):112-120. PubMed ID: 29477373
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incretin-based drugs for type 2 diabetes: Focus on East Asian perspectives.
    Seino Y; Kuwata H; Yabe D
    J Diabetes Investig; 2016 Apr; 7 Suppl 1(Suppl 1):102-9. PubMed ID: 27186364
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glucagon-like-peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes in diabetes in relation to achieved glycemic control. A Danish nationwide study.
    Zareini B; Sørensen KK; Pedersen-Bjergaard U; Loldrup Fosbøl E; Køber L; Torp-Pedersen C
    J Diabetes; 2024 Jun; 16(6):e13560. PubMed ID: 38751369
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes.
    Nauck MA; Petrie JR; Sesti G; Mannucci E; Courrèges JP; Lindegaard ML; Jensen CB; Atkin SL;
    Diabetes Care; 2016 Feb; 39(2):231-41. PubMed ID: 26358288
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes.
    Andersen A; Knop FK; Vilsbøll T
    Drugs; 2021 Jun; 81(9):1003-1030. PubMed ID: 33964002
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-World Effectiveness of Once-Weekly Semaglutide From a US Commercially Insured and Medicare Advantage Population.
    Visaria J; Uzoigwe C; Swift C; Dang-Tan T; Paprocki Y; Willey VJ
    Clin Ther; 2021 May; 43(5):808-821. PubMed ID: 33785221
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
    Ahrén B; Masmiquel L; Kumar H; Sargin M; Karsbøl JD; Jacobsen SH; Chow F
    Lancet Diabetes Endocrinol; 2017 May; 5(5):341-354. PubMed ID: 28385659
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.